Integral DiagnosticsASX:IDX -0.50%73 EBITDA Margin % is 17.21% as of Dec. 2025, which is 11% below its 10-year median of 19.28. GuruFocus rates ASX:IDX with a GF Score™ of 73/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 64.22% on this metric.
Integral Diagnostics (ASX:IDX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Integral Diagnostics EBITDA Margin % Related Terms
Integral Diagnostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDX vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a EBITDA Margin % of 17.21% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integral Diagnostics and its competitors. This is 11% below median its historical median of 19.28. Over the past decade, Integral Diagnostics' EBITDA Margin % has ranged from 1.43 to 25.53. According to the industry distribution chart, Integral Diagnostics ranks #73 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 35.8%.
Is Integral Diagnostics' EBITDA Margin % too high?
Integral Diagnostics' current EBITDA Margin % of 17.21% is 11% below median its 10-year median of 19.28. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 25.53. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Integral Diagnostics' value of 17.21% is 231% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #73 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #73 out of 204 companies for EBITDA Margin %. This puts Integral Diagnostics in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Integral Diagnostics' value of 17.21% is 231% above this benchmark. Historically, Integral Diagnostics' own EBITDA Margin % has ranged from 1.43 to 25.53 over the past decade. While the company's 10-year median is 19.28 vs. the industry median of 5.20, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current EBITDA Margin % of 17.21% is 231% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current EBITDA Margin % is 17.21%, which is 11% below median its own 10-year median of 19.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current EBITDA Margin % is 17.21%, which is 11% below median its 10-year median of 19.28 and 231% above the Medical Diagnostics & Research industry median of 5.20. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current EBITDA Margin % is 17.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
EBITDA Margin %: 17.21% (11% below median its 10-year median of 19.28)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
Industry Position: 231% above the Medical Diagnostics & Research median (#73 of 204)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score
Get the complete analysis for ASX:IDX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
